Search research articles
Contact Us
Filters
Showing results (311-320 of 505) with videos related to
Page
of 51
Sort By:
NPJ Primary Care Respiratory Medicine
|
January 9, 2020
Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)
Nicolas Roche, Vicente Plaza, Vibeke Backer, et al.
Pulmonary Pharmacology & Therapeutics
|
April 7, 2025
The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance
Michela Salvadori, Dave Singh, Kusum Mathews, et al.
Thorax
|
May 11, 2025
Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial
Alexander G Mathioudakis, Andrew Higham, Sebastian Bate, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
March 19, 2019
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
Anthony D D'Urzo, Dave Singh, James F Donohue, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
July 1, 2024
COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US
Fernando J Martinez, Alberto Papi, Tobias Welte, et al.
Respiratory Medicine
|
October 18, 2022
Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis
Kittipong Maneechotesuwan, Dave Singh, Leandro G Fritscher, et al.
Pulmonary Pharmacology & Therapeutics
|
April 22, 2014
The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size
Mirco Govoni, Annalisa Piccinno, Germano Lucci, et al.
Pharmacology Research & Perspectives
|
February 19, 2015
Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial
Joanna C Betts, Ruth J Mayer, Ruth Tal-Singer, et al.
BMC Pulmonary Medicine
|
March 14, 2014
Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD
Dave Singh, Gabriele Nicolini, Eddi Bindi, et al.
Advances in Therapy
|
August 11, 2020
Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO<sup>®</sup>/DYNAGITO<sup>®</sup> Trials
Jadwiga A Wedzicha, Roland Buhl, Dave Singh, et al.
Page
of 51
Search research articles
Search
Showing results (311-320 of 505) with videos related to
Sort By:
Page
of 51
NPJ Primary Care Respiratory Medicine
|
January 9, 2020
Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)
Nicolas Roche, Vicente Plaza, Vibeke Backer, et al.
Pulmonary Pharmacology & Therapeutics
|
April 7, 2025
The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance
Michela Salvadori, Dave Singh, Kusum Mathews, et al.
Thorax
|
May 11, 2025
Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial
Alexander G Mathioudakis, Andrew Higham, Sebastian Bate, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
March 19, 2019
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
Anthony D D'Urzo, Dave Singh, James F Donohue, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
July 1, 2024
COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US
Fernando J Martinez, Alberto Papi, Tobias Welte, et al.
Respiratory Medicine
|
October 18, 2022
Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis
Kittipong Maneechotesuwan, Dave Singh, Leandro G Fritscher, et al.
Pulmonary Pharmacology & Therapeutics
|
April 22, 2014
The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size
Mirco Govoni, Annalisa Piccinno, Germano Lucci, et al.
Pharmacology Research & Perspectives
|
February 19, 2015
Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial
Joanna C Betts, Ruth J Mayer, Ruth Tal-Singer, et al.
BMC Pulmonary Medicine
|
March 14, 2014
Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD
Dave Singh, Gabriele Nicolini, Eddi Bindi, et al.
Advances in Therapy
|
August 11, 2020
Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO<sup>®</sup>/DYNAGITO<sup>®</sup> Trials
Jadwiga A Wedzicha, Roland Buhl, Dave Singh, et al.
Page
of 51